Dogwood Therapeutics Inc

Dogwood Therapeutics has a market capitalization of $66.14 million and a price-to-book ratio of 0.88, indicating that the company is trading at a discount relative to its book value. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. The current ratio of 2.76 indicates that the company has sufficient current assets to cover its current liabilities.

The company's financial performance is weak, with a return on equity of -45.74% and a return on assets of -37.99%. These negative returns suggest that the company is not generating profits relative to its equity or asset base. The operating cash flow of -$15.62 million and free cash flow of -$35.51 million indicate that the company is consuming cash rather than generating it, which is a concern for long-term sustainability.

Dogwood Therapeutics does not report segment or geographic revenue data in the provided financials, so it is not possible to assess revenue concentration or geographic exposure. However, the company's operations are likely concentrated in the United States, as is typical for biotechnology firms.

The company's outlook for the current fiscal year is negative, with no revenue reported and a net loss of $34.26 million. The lack of revenue and continued losses suggest that the company is in the early stages of development and has not yet commercialized its products. The company will need to achieve significant milestones in clinical trials or product development to turn this trajectory around.

The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the company's negative cash flows and lack of revenue suggest that it may need to raise additional capital in the future, which could lead to dilution for existing shareholders. The company has not issued any recent equity, and there is no indication of dilution pressure in the near term.

Recent events include the publication of the latest financial data, which shows continued losses and negative cash flows. There are no recent filings or transcripts indicating significant changes in the company's strategy or operations. The company's price target from analysts ranges from $12 to $15, with a mean of $14 and a median of $15, suggesting that analysts have a generally positive outlook despite the company's current financial performance.